Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)

Exclusion Criteria

• •No prior systemic treatment for locally advanced or metastatic NSCLC
• •High tumor cell PD-L1 expression \[Tumor Proportion Score (TPS) ≥50%\] based on documented status as determined by an approved test
• •Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
• •Measurable disease as determined by RECIST v1.1
• •Tumors harboring driver mutations/genetic aberrations for which targeted therapies are approved as frontline treatment (e.g. EGFR mutation, ALK fusion oncogene, ROS1 aberrations)
• •Prior immune checkpoint inhibitor therapy
• •Active brain metastases
• •Participants with active and uncontrolled hepatitis B virus (HBV) or hepatitis C virus (HCV) infection
• •Uncontrolled HIV infection. Participants with HIV who have controlled infection (undetectable viral load and CD4 count above 350 either spontaneously or on a stable antiviral regimen) are allowed to enroll
• •Active, known or suspected autoimmune disease or immune deficiency
• •History of hypersensitivity reactions to any ingredient of the investigational medicinal product (IMP) and other monoclonal antibody (mAbs) and/or their excipients
• •History of interstitial lung disease, idiopathic pulmonary fibrosis, drug-induced pneumonitis, idiopathic pneumonitis or active pneumonitis ≥ grade 2
• •History of inflammatory bowel disease or colitis ≥ grade 2
• •History of hemophagocytic lymphohistiocytosis.
• •Systemic chronic steroid therapy (\>10mg/d prednisone or equivalent)
• •Clinically significant infection, as assessed by the investigator
• •Pregnant or breast-feeding (lactating) women
• •Participants with a history of allogeneic organ transplantation (e.g., stem cell or solid organ transplant)
• •Any medical condition that would in the investigator's judgement prevent the participant's participation in the clinical study